Abstract:The present work describes the synthesis and docking of heterocyclically substituted glycinamide derivatives. These derivatives are assessed in vitro for DPP 4 inhibition. Compound 2‐(4‐fluorophenethylamino)‐1‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)piperidin‐1‐yl)ethan‐1‐one (JAG‐D2), showing promising results during in vitro assessment was evaluated in vivo using OGTT assay in streptozotocin‐induced diabetic rats. The structure‐activity relationship studies based the binding mode of glycinamide derivatives and MD simulation of JAG‐D2 are discussed. According to the International Diabetes Federation, the global prevalence of diabetes is projected to increase to 643 million individuals by 2030 and 783 million by 2045. DPP 4 inhibitors approved by regulatory authorities worldwide, efficiently to regulate high blood sugar levels by impeding the degradation of glucagon like peptide‐1 (GLP‐1), an incretin hormone, prolonging the physiological effects of GLP‐1. In the present research work, a total of 12 glycinamide‐based compounds with aromatic substituents on the N‐terminus and heterocycles like piperidine, 4‐phenylpiperazine, and 6‐fluorobenzo[d]isoxazol‐3‐piperidine on the C‐terminus were synthesized and characterized. The synthesized compounds were subjected to in vitro DPP 4 inhibition assay. The promising compound JAG‐D2 was evaluated in vivo using OGTT assay in streptozotocin‐induced diabetic rats. JAG‐D2 produced a significant reduction in blood glucose levels at 20 mg/kg and 40 mg/kg doses when compared with a 1 mg/kg dose of the reference standard sitagliptin. The synthesized compounds occupied the active site of DPP 4 as demonstrated in molecular docking and MM‐GBSA analysis for rescoring on the basis of binding free energy. Molecular dynamics studies displayed the stability of the docked pose of JAG‐D2 in the catalytic site of DPP 4. All compounds exhibited compliance with Lipinski's rule of five, suggesting drug‐like properties.

Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Synthesis of β-Amino Carbonyl 6-(Aminomethyl)- and 6-(Hydroxymethyl)pyrazolopyrimidines for DPP-4 Inhibition Study

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Novel DPP-4 Inhibitors Against Diabetes

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

(R)-3-amino-1-((3as,7as)-octahydro-1h-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Derivatives As Potent Inhibitors of Dipeptidyl Peptidase-4: Design, Synthesis, Biological Evaluation, and Molecular Modeling.

Synthesis of 1,2,3-Triazole Analogs of Linagliptin as Novel DPP-4 Inhibitors: DFT, Molecular Docking Approach

Discovery of the selective and nanomolar inhibitor of DPP-4 more potent than sitagliptin by structure-guided rational design

Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents

Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors

Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

Computational Simulation Studies, Synthesis, In Vitro, and In Vivo Evaluation of Heterocyclically Substituted Glycinamide Derivatives as DPP 4 Inhibitors

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-methanoprolinenitrile-based Inhibitors.

Synthesis and Biological Evaluation of Azobicyclo[3.3.0] Octane Derivatives As Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes

Stereochemical insights into β-amino-N-acylhydrazones and their impact on DPP-4 inhibition

Structural Optimization of Pyrazolo[1,5-A]pyrimidine Derivatives As Potent and Highly Selective DPP-4 Inhibitors.

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.